Prevention of Chemotherapy-induced Nausea and Vomiting

Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV): Background

Antiemetic Therapy in the Setting of Chemotherapy: The Goal

Impact of CINV on Quality of Life:Complete Control of CINV vs Failure to Control

CINV

Some of the Pathways Underlying CINV

Some Pathway Triggers Involved in CINV

Clinical Factors Contributing to CINV

Clinician Underestimation of CINV Has Been Demonstrated

CINV: Nuts and Bolts

Not All Chemotherapy is Alike When it Comes to CINV: Emetic

Risk of Chemotherapy

Not All Chemotherapy is Alike When it Comes to CINV: Emetic

Risk of Chemotherapy (cont)

Importance of Recognizing CINV Risk Factors

The Major Presentations of CINV

Antiemetic Guidelines

Antiemetic Guidelines

Antiemetic Agents in Antiemetic Guidelines

2013 MASCC/ESMO Antiemetic Guideline Recommendations:

Acute Setting

2013 MASCC/ESMO Antiemetic Guideline Recommendations:

Delayed Setting

HEC: Evidence for MASCC/ESMO Recommendation

AC: Evidence for MASCC/ESMO Recommendation

Non-AC MEC: Evidence for MASCC/ESMO Recommendation

5HT3 RAs: Mechanism of Action

Safety and Antiarrhythmic Issues With Some 5HT3 RAs

Aprepitant or Fosaprepitant: IV or Oral NK1 RA Agent Comparison: Results of a Large

Randomized Trial

Minimal Emetic Risk Chemotherapy

Anticipatory CINV

High Level of Agreement Across 3 Major Antiemesis Guidelines:

Similarities and Differences

Evidence That Guideline-Based Care is Effective in the Prevention

of CINV

Strategies for Monitoring the Effectiveness of Antiemetic

Therapy and Enhancing Patient-Clinician Communication About

CINV

The MASCC Antiemesis Tool

Challenges and Opportunities in the Prevention of CINV

CINV Prevention: A Brief Look Ahead

Summary

Abbreviations

Abbreviations (cont)